The Effective Role of Adding Letrozole to Methotrexate in the Management of Tubal Ectopic Pregnancies, a Randomized Clinical Trial

Document Type : Research article

Authors

1 Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran.

2 Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.

3 Arash Women Hospital, Tehran University of Medical Sciences, Tehran, Iran.

10.22037/ijpr.2021.115659.15461

Abstract

Ectopic pregnancy (EP) is considered a main reproductive health challenge. According to the side effects of using methotrexate (MTX), it is rational to find safer drugs in the management of EP. This randomized controlled trial aimed to evaluate the efficacy and safety of adding letrozole to the single-dose MTX in the management of EPs. This study was conducted in an academic hospital affiliated to Tehran University of Medical Sciences. Women with EP and stable vital signs with β-hCG levels ≤3500 were assigned randomly to receive MTX + placebo or MTX + letrozole. The regression pattern of β-hCG, need for further surgery, and potential side effects were compared between groups. A total of 90 women were assigned equally to the study groups and were matched in age, body mass index (BMI), serum biochemistry, and primary levels of β-hCG. No drug-related side effects were observed in groups. The rates of further surgery (p = 0.614) and second dose of MTX (p = 0.809) were not significant between groups. In the MTX + placebo group, we observed a minor increase in β-hCG levels on day 4 followed by a decreasing pattern on days 7 and 14. But, in MTX + letrozole group, a decreasing pattern in β-hCG levels from day 1 through day 14 was perceived. The results support using MTX + letrozole to treat stable women diagnosed with tubal EP as a safe and efficient method. Further studies are required to evaluate letrozole alone as an alternative therapy in EPs.

Graphical Abstract

The Effective Role of Adding Letrozole to Methotrexate in the Management of Tubal Ectopic Pregnancies, a Randomized Clinical Trial

Keywords

References

References
(1) Sivalingam VN, Duncan WC, Kirk E, Shephard
LA and Horne AW. Diagnosis and management of
ectopic pregnancy. J. Fam. Plann. Reprod. Health
Care (2011) 37: 231-40.
(2) Lee R, Dupuis C, Chen B, Smith A and Kim YH.
Diagnosing ectopic pregnancy in the emergency
setting. Ultrasonography (2018) 37: 78-87.
(3) Mello NM, Mol F, Ankum WM, Mol BW, Veen
F and Hajenius PJ. Ectopic pregnancy: how
the diagnostic and therapeutic management has
changed. Fertil Steril (2012) 98: 1066-73.
(4) Practice Committee of American Society for
Reproductive, M., Medical treatment of ectopic
pregnancy: a committee opinion. Fertil Steril
(2013) 100: 638-44.
(5) Zhuo Y, Cainuo S, Chen Y and Sun B. The efficacy
of letrozole supplementation for medical abortion:
a meta-analysis of randomized controlled trials. J.
Matern-Fetal Neonatal Med. (2021) 34: 1501-7.
(6) Palomba S. Aromatase inhibitors for ovulation
induction. J. Clin. Endocrinol. Metab. (2015) 100:
1742-7.
(7) Mitwally M.F, Hozayen WG, Hassanin K, Abdalla
KA and Abdalla NK. Aromatase inhibitor letrozole:
a novel treatment for ectopic pregnancy. Fertil
Steril (2020) 114: 361-6.
(8) Auger N, Ayoub A and Wei SQ. Letrozole: future
alternative to methotrexate for treatment of ectopic
pregnancy? Fertil Steril (2020) 114: 273-4.
(9) Aoyama T, Paik YH, Watanabe S, Laleu B,
Gaggini F, Fioraso-Cartier L, Molango S, Heitz F,
Merlot C, Szyndralewiez C, Page P and Brenner
DA. Nicotinamide adenine dinucleotide phosphate
oxidase in experimental liver fibrosis: GKT137831
as a novel potential therapeutic agent. Hepatology
384
Letrozole in Management of Ectopic Pregnancy
(2012) 56: 2316-27.
10. Weiss A, Beck-Fruchter R, Golan J, Lavee M,
Geslevich Y and Shalev E. Ectopic pregnancy risk
factors for ART patients undergoing the GnRH
antagonist protocol: a retrospective study. Reprod.
Biol. Endocrinol. (2016) 14: 12.
(11) Lawani OL, Anozie OB and Ezeonu PO. Ectopic
pregnancy: a life-threatening gynecological
emergency. Int. J. Womens Health (2013) 5: 515-21.
(12) Natale A, Candiani M, Barbieri M, Calia C,
Odorizzi MP and Busacca M. Pre- and post treatment
patterns of human chorionic gonadotropin for early
detection of persistence after a single dose of
methotrexate for ectopic pregnancy. Eur. J. Obstet.
Gynecol. Reprod. Biol. (2004) 117: 87-92.
(13) Rezai Z, Ghasemi Nezhad A, Sadeghi AS and
Ghorbani YB. Letrozole and misoprostol versus
misoprostol alone for termination of pregnancy:
A randomized clinical trial. Iran. J. Endocrinol.
Metab. (2014) 71: 700–6.
(14) Albrecht ED, Aberdeen GW and Pepe GJ. The
role of estrogen in the maintenance of primate
pregnancy. Am. J. Obstet. Gynecol. (2000) 182:
432-8.
(15) Yeung TW, Lee VCY, Hung E and Chung P. A
pilot study on the use of a 7-day course of letrozole
followed by misoprostol for the termination of
early pregnancy up to 63 days. Contraception
(2012) 86 (6): 763-9.
(16) Nash CM, Philp L, Shah P and Murphy KE.
Letrozole pretreatment prior to medical termination
of pregnancy: a systematic review. Contraception
(2018) 97: 504-9.
(17) Sorensen HT, Lash TL and Rothman KJ. Beyond
randomized controlled trials: a critical comparison
of trials with nonrandomized studies. Hepatology
(2006) 44: 1075-82
Iranian Journal of Pharmaceutical Research
Volume 20, Issue 4
Autumn 2021
Pages 378-384

Files

Share

How to cite

Statistics